A survey of Navy physicians' attitudes toward the use of selective serotonin reuptake inhibitors in active duty military personnel.
A series of recent pharmacological discoveries have produced remarkable advances in psychotherapeutic medications. With the advent of newer antidepressants, there is a high degree of efficacy and a low risk profile. Potential benefits of these medications far outweigh the possible side effects, especially in contrast to older drugs. Navy Medicine now has the ability to treat active duty personnel during a deployment with safe antidepressant medications. The attitudes toward the use of selective serotonin reuptake inhibitors (SSRIs) on active duty service members has been surveyed. Profiles of prescribing patterns and attitudes toward the use of these medications and safety within the context of the operational environment were also surveyed. Group comparisons across various medical specialties and command organizations were made. The survey results suggest a very favorable attitude toward prescribing SSRIs in the active duty population.